| Literature DB >> 35566659 |
Francesca Buonomo1, Sofia Bussolaro2, Clarice de Almeida Fiorillo1, Danilo Oliveira de Souza3, Fabiola Giudici2,4, Federico Romano1, Andrea Romano5, Giuseppe Ricci1,2.
Abstract
AIM: The aim of this study was to evaluate the feasibility of adequacy, accuracy, and safety of ultrasound-guided tru-cut biopsy in managing malignant and benign abdominopelvic masses in a selected population and critically discuss some issues in different situations, which deserve some reflections on those practices.Entities:
Keywords: gynecological oncological diseases; tru-cut biopsy; ultrasound
Year: 2022 PMID: 35566659 PMCID: PMC9101565 DOI: 10.3390/jcm11092534
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1The US image of a highly vascularized cervical squamous cancer relapse (left) and the clear image of the tru-cut needle inside the lesion during the procedure (right).
Characteristics of the patients.
| Variables | N = 42 Patients |
|---|---|
| Age (years): Median (min-max) | 72 (39–93) |
| Body Mass Index (Kg/m2): Median (min-max) | 24.9 (18.6–42.5) |
| CA-125 UI/L: Median (min-max) | 129 (3–2358.3) |
| Personal history of cancer (N, %) | 15 (35.7%) |
|
| |
| Inoperable advanced tumor (N, %) | 23 (54.8%) |
| Poor performance status (N, %) | 16 (38%) |
| Suspicion of recurrence (N, %) | 11 (26.1%) |
| Suspicion of metastases | 3 (7.1%) |
| Previously undefined malignancies (N, %) | 1 (2.3%) |
US features and final pathology.
| Variables | N = 42 Patients |
|---|---|
| Largest diameter of the lesion (mm): median (min-max) | 51 (8–280) |
|
| |
| Solid | 34 (81%) |
| Multilocular-solid | 8 (19 %) |
|
| |
| Irregular | 36 (85.7%) |
| Regular | 6 (14.3%) |
|
| |
| 2 | 10 (23.8%) |
| 3 | 29 (69%) |
| 4 | 3 (7.1%) |
| Ascites (N, %) | 12 (28.6%) |
|
| |
| Transvaginal | 31 (73.8%) |
| Transabdominal | 11 (26.2%) |
|
| |
| Lesion | 34 (81%) |
| Omental cake | 4 (10%) |
| Carcinosis | 4 (10%) |
|
| |
| Benign | 2 (4.8%) |
| Malign | 40 (95.2%) |
| Primary advanced tumors | 27 (67.5%) |
| Advanced ovarian cancer | 19 (47.5%) |
| Advanced cervical cancer | 7 (17.5%) |
| Recurrent genital tumors | 10 (25%) |
| Recurrence of endometrial cancer | 4 (10%) |
| Recurrence of cervical cancer | 3 (7.5%) |
| Recurrence of ovarian cancer | 3 (7.5%) |
| Primary peritoneal cancer in an oncological patient | 1 (2.5%) |
| Metastases or non-genital malignancy | 3 (7.5%) |
| Complications (mild) (N, %) | 1 (2.4%) |
Figure 2Transvaginal US picture of a multilocular-solid lesion with papillary projections (high-grade clear cell adenocarcinoma of the ovary).
Figure 3The US image of the pelvic B lymphoma shows a solid lesion with irregular and shaded margins and a color score of 4 between the urethra and the pubic bone.
Figure 4The US images of ascites, diffuse pelvic and abdominal parietal, and visceral carcinomatosis (a), omental cake (b), the presumed involvement of the mesenteric radix (c), a nodule of carcinomatosis on the descending colon (d) in a plausible clinical picture of inoperability.
Figure 5On the (left): 2D US images with VCI of a solid neoformation from the vaginal dome in a patient with a previous diagnosis of endometrial cancer. On the (right): Doppler US image of the same neoformation highlighting the vascularization in the lesion.